ArticleJournal of thoracic disease2026
Interpretable machine learning model integrating delta-radiomics enhances postoperative recurrence prediction in early-stage lung adenocarcinoma.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite curative resection for early-stage lung adenocarcinoma (LUAD), postoperative recurrence remains a significant concern, with substantial outcome heterogeneity even among patients with stage IA disease. An accurate tool to identify individuals at high risk of early postoperative recurrence after curative resection is urgently needed to guide intensified surveillance and adjuvant strategies. Therefore, the objective of this study was to develop and validate an interpretable machine learning model integrating clinical-radiological features, radiomics, and delta-radiomics to predict early postoperative recurrence in stage IA LUAD. Methods: This retrospective study included 463 patients with pathologically confirmed stage IA LUAD who underwent curative surgery. Preoperative serial computed tomography (CT) scans (baseline and follow-up) were used to extract radiomics and delta-radiomics features, the latter quantifying temporal changes in tumor phenotype. Clinical and conventional radiological variables were also collected. After random allocation to training and validation cohorts, the Synthetic Minority Oversampling Technique (SMOTE) was applied to address class imbalance. Feature selection was performed using univariate analysis, correlation analysis, and Random Forest with five-fold cross-validation. A fusion model integrating clinical-radiological features, radiomics score (Rad-score), and Delta Rad-score was developed using a Random Forest algorithm. Model performance was assessed by area under the curve (AUC), calibration, and decision curve analysis. Shapley additive explanations (SHAP) were used for model interpretability. Prognostic value for recurrence-free survival (RFS) and overall survival (OS) was evaluated using Kaplan-Meier analysis and compared with traditional tumor-node-metastasis (TNM) staging. Results: Among 463 patients (median age 57 years; 156 males), 23 (5.0%) experienced early recurrence. The fusion model demonstrated excellent discrimination in the validation cohort (AUC: 0.881), significantly outperforming the clinical model (AUC: 0.725), with comparable discrimination to the radiomics model (AUC: 0.845) and delta-radiomics model (AUC: 0.827). Calibration was good (Brier score: 0.021), and decision curve analysis confirmed the highest net clinical benefit for the fusion model. SHAP analysis identified Rad-score and Delta Rad-score as the most important predictors, with higher values associated with increased recurrence risk. The fusion model stratified patients into high- and low-risk groups with significant differences in both RFS and OS (log-rank P<0.001 for both), whereas TNM staging (T1c Conclusions: The interpretable machine learning model integrating clinical-radiological features, radiomics, and delta-radiomics demonstrated promising predictive performance in internal validation of early postoperative recurrence in stage IA LUAD compared with traditional models and TNM staging. Delta-radiomics captures dynamic tumor evolution and emerges as a key prognostic biomarker. This model offers a non-invasive tool for individualized risk stratification to guide postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.